US20150174093A1 - Compositions comprising sulforaphane or a sulforaphane precursor and magnesium - Google Patents

Compositions comprising sulforaphane or a sulforaphane precursor and magnesium Download PDF

Info

Publication number
US20150174093A1
US20150174093A1 US14/412,189 US201314412189A US2015174093A1 US 20150174093 A1 US20150174093 A1 US 20150174093A1 US 201314412189 A US201314412189 A US 201314412189A US 2015174093 A1 US2015174093 A1 US 2015174093A1
Authority
US
United States
Prior art keywords
sulforaphane
magnesium
subject
orally administrable
administrable composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/412,189
Other languages
English (en)
Inventor
Brian Cornblatt
Grace Cornblatt
Anton Bzhelyansky
Robert Henderson
Ronald Kettenacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutramax Laboratories Inc
Original Assignee
Nutramax Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49882601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20150174093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutramax Laboratories Inc filed Critical Nutramax Laboratories Inc
Priority to US14/412,189 priority Critical patent/US20150174093A1/en
Assigned to NUTRAMAX LABORATORIES, INC. reassignment NUTRAMAX LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HENDERSON, ROBERT, BZHELYANSKY, Anton, CORNBLATT, Brian, CORNBLATT, Grace, KETTENACKER, RONALD
Publication of US20150174093A1 publication Critical patent/US20150174093A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01147—Thioglucosidase (3.2.1.147), i.e. myrosinase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof.
  • the present invention also relates to the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof.
  • the present invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof.
  • the present invention provides compositions and methods relating to these combinations.
  • cardiovascular disease More than 1 in 3 (83 million) U.S. adults currently live with one or more types of cardiovascular disease. Respectively, heart disease and stroke are the first and third leading causes of death in the US with an estimated 935,000 heart attacks and 795,000 strokes occurring each year. Nearly 68 million adults have high blood pressure, and about half have uncontrolled hypertension. Additionally, an estimated 71 million adults have high cholesterol (i.e., high levels of low-density lipoprotein cholesterol), with an estimated 2 ⁇ 3 of this population having uncontrolled high cholesterol. These health problems are among the most widespread and costly of chronic illnesses in the United States today, accounting for approximately one out of every six dollars spent on healthcare. At the “heart” of cardiovascular disease is endothelial dysfunction.
  • Endothelium a thin membrane of flattened cells that line all blood vessels, is one of the largest organs in the body.
  • the vascular endothelia play vital roles in blood flow, blood pressure regulation, coagulant and anticoagulant activity as well as control the selective adhesion and tissue migration of white blood cells.
  • Endothelial dysfunction is the greatest underlying cause of atherosclerosis, hypertension, and inflammatory vascular diseases that lead to many of the catastrophic heart, circulatory, renal, and neurological conditions affecting the population. Endothelial dysfunction which invariably leads to major cardiovascular events, is most often due to a chronic inflammatory state brought on by conditions such as diabetes (both type 2 and insulin dependent diabetes), immune disorders (eg.
  • CRP C-Reactive Protein
  • IL-8 Interleukin-8
  • MCP-1 monocyte chemoattractant protein
  • Chemoprotection through the use of natural products is evolving as a safe, effective, inexpensive, easily accessible, and practical means to prevent or reduce the occurrence of many conditions affecting humans and domesticated animals. It is known that carcinogens which can damage cells at the molecular level are often ingested and inhaled as non-toxic precursors. These non-toxic precursors may then convert into carcinogenic substances in the body. Chemoprotective agents, such as natural substances which can activate detoxifying enzymes or their co-factors, can counteract and allow for the elimination of carcinogens. These same natural substances can potentiate other naturally existing defenses such as the immune system.
  • Atherosclerosis results from a number of different inflammatory cascades.
  • Evidence points to monocyte-derived macrophages as being one of the key cell types involved in endothelial inflammation.
  • Interleukin-8 (IL-8) is responsible for recruiting monocytes and macrophages and monocyte chemoattractant protein-1 (MCP-1) plays a role in migration and infiltration of these cells.
  • MCP-1 monocyte chemoattractant protein-1
  • diseases and conditions associated with MCP-1 and IL-8 include, but are not limited to atherosclerosis, inflammatory bowel disease, inflammatory lung disease, chronic liver disease, inflammatory rheumatic disease, gingivitis, asthma, psoriasis, Alzheimer's disease, ischemic heart disease, acute coronary syndrome, arterial injury, and arteriogenesis.
  • Oxidative stress plays a major role in aging, the progression of neurodegenerative diseases as well as physiological trauma, such as ischemia.
  • Antioxidant agents can reduce or inhibit the oxidation of vital biomolecules and may play a role in treating, preventing, or reducing the occurrence of conditions affected by oxidative stress.
  • Sulforaphane is an organosulfur compound which is also known as 1-isothiocyanato-4-methylsulfinylbutane.
  • the sulforaphane precursor, glucoraphanin can be obtained from vegetables of the Brassicaceae family, such as broccoli, brussel sprouts, and cabbage. However, copious amounts of vegetables must be consumed in order to obtain levels adequate for chemoprevention.
  • Glucoraphanin is converted into sulforaphane by a thioglucosidase enzyme called myrosinase, which occurs in a variety of exogenous sources such as Brassicaceae vegetables and endogenously in the gut microflora.
  • myrosinase a thioglucosidase enzyme
  • glucoraphanin upon ingestion of glucoraphanin, not all animals are capable of achieving its conversion to sulforaphane, most likely due to variations in microflora populations and overall health.
  • glucoraphanin can be converted to inert metabolites.
  • the active metabolite, sulforaphane induces nuclear erythroid-2-related factor (Nrf2) which, in turn, upregulates the production of Phase II detoxification enzymes and cytoprotective enzymes such as glutathione S-transferases, NAD(P)H:quinine oxidoreductase (NQO1), and heme-oxygenase-1 (HO-1).
  • Sulforaphane has been thought to induce the production of these enzymes without significantly changing the synthesis of P-450 cytochrome enzymes.
  • the upregulation of Phase II enzymes is thought to play a role in a variety of biological activities, including the protection of the brain from cytotoxicity, the protection of the liver from the toxic effects of fat accumulation, and the detoxification of a variety of other tissues.
  • Magnesium is a mineral that is important for many systems in the body, including muscles and nerves. Magnesium is vital for the metabolism of adenosine triphosphate (ATP) and is necessary for protein, fat, and nucleic acid synthesis. Adequate magnesium levels are important for the prevention of hypertension, which is a major cause of endothelial dysfunction. Magnesium is also important for calcium absorption, calcium regulation, and bone mineralization. While there are many magnesium salt forms that can augment dietary magnesium intake, the chelated form of magnesium (magnesium chelate) has been found to provide improved bioavailability of magnesium while providing a decreased side effect profile. For example, compared to salts of magnesium such as magnesium sulfate, magnesium chelates have been found to exert a decreased laxative effect.
  • Vitamin K2 also known as menaquinone, is a fat-soluble vitamin that has been shown to be essential for calcium regulation in the body. Menaquinone occurs naturally in various molecular forms, characterized by the number of isoprene side chains (n), and designated as menaquinone-n (MK-n). MK-7 is most readily obtained through the fermentation of soybeans to make natto. Low levels of vitamin K2 are associated with vascular calcification, including calcification of atherosclerotic plaques, and osteopenic and osteoporotic conditions. Supplementation with vitamin K2 may decrease cholesterol plaque calcification, decrease arterial stiffness, and improve bone mineralization. Zhang et al. ( Proc.
  • European Patent Application No. 2 213 280 discloses formulations comprising glucosinolates such as glucoraphanin and myrosinase, wherein the formulation is encapsulated or coated.
  • the present invention provides a composition
  • a composition comprising: (i) a sulforaphane precursor, preferably glucoraphanin; (ii) an enzyme capable of converting the sulforaphane precursor to sulforaphane, preferably a glucosidase enzyme, more preferably a thioglucosidase enzyme, and most preferably myrosinase; (iii) an enzyme potentiator, preferably ascorbic acid; and (iv) magnesium or a salt or complex thereof.
  • the present invention also provides a method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of, conditions associated with the endothelium and cardiovascular system, comprising administering to the subject: (i) a sulforaphane precursor, (ii) an enzyme capable of converting the sulforaphane precursor to sulforaphane, (iii) an enzyme potentiator, and (iv) magnesium or a salt or complex thereof.
  • the present invention also provides a method of decreasing levels or decreasing gene expression of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject, comprising administering to the subject: (i) a sulforaphane precursor, (ii) an enzyme capable of converting the sulforaphane precursor to sulforaphane, (iii) an enzyme potentiator, and (iv) magnesium or a salt or complex thereof.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • the present invention also provides a method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1), comprising administering to the subject: (i) a sulforaphane precursor, (ii) an enzyme capable of converting the sulforaphane precursor to sulforaphane, (iii) an enzyme potentiator, and (iv) magnesium or a salt or complex thereof.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • the present invention provides a composition comprising: (i) sulforaphane or a derivative thereof, and (ii) magnesium or a salt or complex thereof.
  • the present invention also provides a method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of, conditions associated with the endothelium and cardiovascular system in a subject, comprising administering to the subject: (i) sulforaphane or a derivative thereof, and (ii) magnesium or a salt or complex thereof.
  • the present invention also provides a method of decreasing levels or decreasing gene expression of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject, comprising administering to the subject, comprising administering to the subject: (i) sulforaphane or a derivative thereof, and (ii) magnesium or a salt or complex thereof.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • the present invention also provides a method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1), comprising administering to the subject: (i) sulforaphane or a derivative thereof, and (ii) magnesium or a salt or complex thereof.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • the present invention provides a composition comprising: (i) a broccoli extract or powder, and (ii) magnesium or a salt or complex thereof.
  • the present invention also provides a method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of, conditions associated with the endothelium and cardiovascular system in a subject, comprising administering to the subject: (i) a broccoli extract or powder, and (ii) magnesium or a salt or complex thereof.
  • the present invention also provides a method of decreasing levels or decreasing gene expression of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject, comprising administering to the subject, comprising administering to the subject: (i) a broccoli extract or powder, and (ii) magnesium or a salt or complex thereof.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • the present invention also provides a method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject, comprising administering to the subject: (i) a broccoli extract or powder, and (ii) magnesium or a salt or complex thereof.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • FIG. 1 is a graph showing the conversion of glucoraphanin at 38° C. without ascorbic acid, as described in Example 4.
  • FIG. 2 is a graph showing the conversion within about 10 minutes at 38° C. as a function of ascorbic acid concentration, as described in Example 4.
  • FIG. 3 is a graph showing the conversion to sulforaphane within 30 minutes at 38° C. and 1 mM ascorbic acid, as described in Example 4.
  • FIG. 4 is a graph showing the conversion of glucoraphanin to sulforaphane in simulated intestinal fluid, as described in Example 5.
  • FIG. 5 is a graph showing the results of the experiment described in Example 6.
  • the present invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof.
  • the present invention also relates to the combination of sulforaphane or a derivative thereof and magnesium or a salt or complex thereof.
  • the present invention also relates to the combination of a broccoli extract or powder and magnesium or a salt or complex thereof.
  • the present invention also relates to the use of magnesium or a salt or complex thereof, with a mixture of one or more of the following: sulforaphane precursor, sulforaphane or a derivative thereof, and broccoli extract.
  • the present invention provides compositions relating to these combinations.
  • the present invention also provides methods comprising administering these combinations.
  • the combination may be administered for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with the endothelium and cardiovascular system in a subject.
  • the combination may be administered for decreasing levels or decreasing gene expression of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • the combination may be administered for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1
  • Sulforaphane is also known as 1-isothiocyanato-4-methylsulfinylbutane.
  • Derivatives of sulforaphane include, but are not limited to sulfoxythiocarbamate analogues of sulforaphane, 6-methylsulfinylhexyl isothiocyanate (6-HITC), and compounds which comprise the structure of sulforaphane with different side chains and/or various lengths of spacers between the isothiocyanato and sulfoxide groups.
  • Examples of derivatives of sulforaphane include those described in the following references, each of which is incorporated herein by reference: Hu et al., Eur J Med Chem , 2013, 64:529-539; Ahn et al., Proc Natl Acad Sci USA , 2010, 107(21):9590-9595; and Morimistu et al., J. Biol. Chem . 2002, 277:3456-3463, and Baird et al., Arch Toxicol , 2011, 85(4):241-272.
  • the composition comprises sulforaphane or a derivative thereof, preferably sulforaphane, in an amount of about 1 ⁇ g to about 10 g, preferably about 3 ⁇ g to about 5 g, preferably about 5 ⁇ g to about 1000 mg, preferably about 7 ⁇ g to about 750 mg, more preferably about 10 ⁇ g to about 500 mg, and most preferably about 100 ⁇ g to about 100 mg.
  • compositions suitable for human use comprise about 1 mg to about 20 mg.
  • the methods of the present invention comprise administration of sulforaphane or a derivative thereof to a subject, preferably sulforaphane, in an amount of about 1 ⁇ g to about 10 g, preferably about 3 ⁇ g to about 5 g, preferably about 5 ⁇ g to about 1000 mg, preferably about 7 ⁇ g to about 750 mg, more preferably about 10 ⁇ g to about 500 mg, and most preferably about 100 ⁇ g to about 100 mg.
  • the method comprises administration of about 1 mg to about 20 mg.
  • the methods of the present invention comprise administration of sulforaphane or a derivative thereof to a subject, preferably sulforaphane, in an amount of about 0.01 ⁇ g/kg to about 0.2 g/kg, preferably about 0.05 ⁇ g/kg to about 0.07 g/kg, more preferably about 0.07 ⁇ g/kg to about 15 mg/kg, more preferably about 0.1 ⁇ g/kg to about 11 mg/kg, and most preferably about 0.2 ⁇ g/kg to about 7 mg/kg.
  • the method comprises administration of about 2 ⁇ g/kg to about 2 mg/kg, and more preferably about 0.01 mg/kg to about 0.3 mg/kg.
  • the above amounts may refer to each dosage administration or a total daily dosage.
  • the total daily dosage refers to the total amount of a compound or ingredient which is administered to a subject in a twenty-four hour period.
  • the method comprises administration of more than one of a sulforaphane or a derivative thereof.
  • the compositions comprise more than one of a sulforaphane or a derivative thereof.
  • the methods or composition may comprise both sulforaphane and one or more derivatives thereof, or two or more derivatives.
  • the above amounts may refer to the amount of each sulforaphane or a derivative thereof, or the total amount of the more than one sulforaphane or derivative thereof.
  • sulforaphane precursor refers to any compound, substance or material which can be used to produce sulforaphane.
  • the sulforaphane precursor comprises a compound which can be converted or metabolized to sulforaphane, preferably by an enzyme.
  • the sulforaphane precursor comprises glucoraphanin.
  • Glucoraphanin is a glucosinolate which is also known as 4-methylsulfinylbutyl glucosinolate and 1-S-[(1E)-5-(methylsulfinyl)-N-(sulfonatooxy)pentanimidoyl]-1-thio- ⁇ -D-glucopyranose.
  • the composition comprises about 1 ⁇ g to about 10 g, preferably about 250 ⁇ g to about 5 g, more preferably about 500 ⁇ g to about 2000 mg, even more preferably about 1 mg to about 750 mg, even more preferably about 1.5 mg to about 250 mg, even more preferably about 2 mg to about 100 mg, and most preferably about 3 mg to about 75 mg of the sulforaphane precursor, preferably glucoraphanin.
  • compositions suitable for human use comprise about 3.5 mg to about 50 mg of the sulforaphane precursor, preferably glucoraphanin.
  • the method comprises administering the sulforaphane precursor, preferably glucoraphanin to a subject, in an amount of about 1 ⁇ g to about 10 g, preferably about 250 ⁇ g to about 5 g, more preferably about 500 ⁇ g to about 2000 mg, even more preferably about 1 mg to about 750 mg, even more preferably about 1.5 mg to about 250 mg, even more preferably about 2 mg to about 100 mg, and most preferably about 3 mg to about 75 mg.
  • the method comprises administration of about 3.5 mg to about 50 mg.
  • the method comprises administering an amount of sulforaphane precursor to a subject in an amount of about 1 ⁇ g/kg to about 1000 mg/kg, preferably about 5 ⁇ g/kg to about 500 mg/kg, more preferably about 7.5 ⁇ g/kg to about 100 mg/kg, even more preferably about 10 ⁇ g/kg to about 25 mg/kg, and most preferably about 25 ⁇ g/kg to about 10 mg/kg.
  • the method comprises administration of about 50 ⁇ g/kg to about 800 ⁇ g/kg.
  • the above amounts may refer to each dosage administration or a total daily dosage.
  • the method comprises administration of more than one sulforaphane precursor.
  • the composition comprises more than sulforaphane precursor.
  • the above amounts may refer to the amount of each sulforaphane precursor, or the total amount of the sulforaphane precursors.
  • the sulforaphane precursor may be converted or metabolized to sulforaphane.
  • the sulforphane precursor is converted to sulforaphane by an enzyme.
  • the enzyme capable of converting the sulforaphane precursor to sulforaphane comprises a glucosidase enzyme, preferably a thioglucosidase enzyme, and more preferably myrosinase. Myrosinase is also known as thioglucoside glucohydrolase.
  • the composition comprises the enzyme in an amount of about 1 ⁇ g to about 1 ug, preferably about 50 ⁇ g to about 500 ng, and most preferably about 1 ng to about 150 ng.
  • compositions suitable for human use comprise about 5 ng to about 75 ng of the enzyme.
  • the method comprises administering the enzyme, preferably myrosinase, in an amount of about 1 ⁇ g to about 1 ⁇ g, preferably about 50 ⁇ g to about 500 ng, and most preferably about 1 ng to about 150 ng.
  • the method comprises administration of about 5 ng to about 75 ng of the enzyme.
  • the method comprises administering the enzyme to a subject in an amount of about 0.02 ⁇ g/kg to about 0.02 ug/kg, preferably about 0.7 ⁇ g/kg to about 7 ng/kg, and most preferably about 0.02 ng/kg to about 2 ng/kg.
  • the method comprises administration of about 0.1 ng/kg to about 1 ng/kg.
  • the above amounts may refer to each dosage administration or a total daily dosage.
  • the method comprises administration of more than one enzyme capable of converting the sulforaphane precursor to sulforaphane.
  • the composition comprises more than one enzyme capable of converting the sulforaphane precursor to sulforaphane.
  • the above amounts may refer to the amount of each enzyme, or the total amount of the enzymes.
  • the present invention also provides for the use of a broccoli extract and/or powder, including but not limited to broccoli seed and sprout extracts and powders.
  • the present invention provides methods of administration of broccoli extract and/or powder, and compositions comprising broccoli extract and/or powder.
  • the broccoli extract or powder is standardized to contain about 1 to about 75% w/w, more preferably about 2.5% to about 50%, even more preferably about 5% to about 25%, and most preferably about 10% to about 20% of a sulforaphane precursor, preferably glucoraphanin.
  • Examples of broccoli extracts and powders include but are not limited to those described in U.S. Pat. Nos.
  • Powders of broccoli may be obtained, for example, by air drying, freeze drying, drum drying, spray drying, heat drying and/or partial vacuum drying broccoli, preferably broccoli sprouts.
  • the compositions and methods comprise use of about 1 ⁇ g to about 10 g, more preferably about 250 ⁇ g to about 5 g, even more preferably about 500 ⁇ g to about 1 g, preferably about 600 ⁇ g to about 500 mg, more preferably about 750 ⁇ g to about 400 mg, and most preferably about 1 mg to about 300 mg of the broccoli extract.
  • the broccoli extract or powder is present in a composition or administered to a subject in amounts sufficient to provide a sulforaphane precursor or sulforaphane in the amounts described above.
  • the composition may further comprise an enzyme potentiator, preferably ascorbic acid.
  • the method may further comprise administration of an enzyme potentiator, preferably ascorbic acid.
  • the sulforaphane or a derivative thereof, the sulforaphane precursor, and/or the enzyme capable of converting the sulforaphane precursor to sulforaphane may be obtained from any source, including but not limited to one or more plants from the Brassicaceae (also known as Cruciferae) family. Examples of plants from the Brassicaceae family include, but are not limited to, the following: broccoli, Brussels sprouts, cauliflower, cabbage, horseradish, parsnip, radish, wasabi, watercress, and white mustard.
  • sulforaphane precursor, preferably glucoraphanin, and the enzyme, preferably myrosinase are obtained from broccoli, broccoli sprouts, or broccoli seeds.
  • the sulforaphane precursor and the enzyme may be obtained from the same source or from different sources. In some embodiments, both the sulforaphane precursor and the enzyme may be obtained from an extract or powder from these plants, preferably a broccoli seed or sprout extract or powder.
  • the present invention provides for the use of an enzyme potentiator.
  • Enzyme potentiators may be used to enhance the activity of the enzyme that is capable of converting the sulforaphane precursor to sulforaphane.
  • the enzyme potentiator comprises an enzyme co-factor, preferably ascorbic acid. Ascorbic acid, also known as ascorbate or vitamin C, can potentiate the activity of myrosinase.
  • Ascorbic acid also known as ascorbate or vitamin C
  • the conversion reaction to sulforaphane may be too slow to occur in the location needed for peak absorption.
  • the enzyme potentiator may be obtained from a natural source, or it may be produced synthetically.
  • compositions may comprise about 1 mg to about 500 mg, preferably about 1 mg to about 250 mg, and most preferably about 1 mg to about 125 mg of the enzyme potentiator. In some preferred embodiments, compositions suitable for human use comprise about 1 mg to about 50 mg of the enzyme potentiator.
  • the method of the present invention comprises administration of an enzyme potentiator, preferably ascorbic acid, in an amount of about 1 mg to about 500 mg, preferably about 1 mg to about 250 mg, and most preferably about 1 mg to about 125 mg. In some preferred embodiments wherein the subject is a human, the method comprises administration of about 1 mg to about 50 mg. In some embodiments, the method of the present invention comprises administration of the enzyme potentiator, preferably ascorbic acid, in an amount of about 0.01 mg/kg to about 3 mg/kg, and most about 0.02 mg/kg to about 2 mg/kg. In some preferred embodiments wherein the subject is a human, the method comprises administration of about 0.02 mg/kg to 0.7 mg/kg of the enzyme potentiator. The above amounts may refer to each dosage administration or a total daily dosage.
  • the method comprises administration of more than one enzyme potentiator.
  • the composition comprises more than one an enzyme potentiator.
  • the above amounts may refer to the amount of each enzyme potentiator, or the total amount of the enzyme potentiators.
  • the present invention further comprises magnesium or a salt or complex thereof.
  • the present invention provides for the use of any compounds containing magnesium, such as magnesium oil.
  • Salts of magnesium include, but are not limited to: magnesium sulfate, magnesium oxide, magnesium citrate, magnesium glutamate, magnesium gluconate, magnesium glycinate, magnesium bromide, magnesium carbonate, magnesium chloride, magnesium fluoride, magnesium iodide, magnesium nitrate, magnesium perchlorate, magnesium permanganate, magnesium phosphate, magnesium oratate, magnesium malate, magnesium aspartate, and dimagnesium malate.
  • Complexes of magnesium include, but are not limited to magnesium chelates, such as magnesium bisglycinate chelate magnesium lysinate glycinate chelate, magnesium glycinate glutamine chelate.
  • the magnesium or a salt or complex thereof comprises magnesium sulfate, magnesium oxide, magnesium citrate, magnesium malate, magnesium glycinate, dimagnesium malate, magnesium bisglycinate chelate, or dimagnesium malate.
  • the compositions the compositions and/or methods of the present invention comprise magnesium malate, or magnesium bisglycinate chelate, which is a form of bioavailable magnesium which presents a low adverse effect and drug interaction profile with a high level of absorption.
  • the compositions and/or methods comprise the use of more than one magnesium or salt or complex thereof.
  • magnesium or a salt or complex thereof may be used.
  • the composition of the present invention comprises about 1 to about 1000 mg, preferably about 5 mg to about 750 mg, more preferably about 10 mg to about 500 mg, and most preferably about 15 mg to about 350 mg. In some preferred embodiments wherein the compositions are suitable for human use, the composition comprises about 20 mg to about 200 mg of elemental magnesium.
  • the method of the present invention comprises administration of about 1 mg to about 1000 mg, preferably about 5 mg to about 750 mg, more preferably about 10 mg to about 500 mg, and most preferably about 15 mg to about 350 mg.
  • the method comprises administration of about 20 mg to about 200 mg of elemental magnesium.
  • the method of the present invention comprises administration of about 0.1 mg/kg to about 15 mg/kg, preferably about 0.15 mg/kg to about 10 mg/kg, more preferably about 0.2 mg/kg to about 7.5 mg/kg, more preferably about 0.3 mg/kg to about 5 mg/kg, and most preferably about 0.3 mg/kg to about 4 mg/kg.
  • the method comprises administration of about 0.3 mg/kg to about 3 mg/kg of elemental magnesium.
  • the above amounts may refer to each dosage administration or a total daily dosage.
  • the method comprises administration of more than magnesium or a salt or complex thereof.
  • the composition comprises more than one type of magnesium or a salt or complex thereof.
  • the above amounts may refer to the amount of each magnesium or a salt or complex thereof, or the total amount of the magnesium or a salt or complex thereof.
  • a vitamin K2 may be further used.
  • the addition of vitamin K2, which is optional, may provide a synergistic effect.
  • Vitamin K2, which is also known as menaquinone can be provided in the form of menaquinone-4 (MK-4), menaquinone-5 (MK-5), menaquinone-6 (MK-6), menaquinone-7 (MK-7), menaquinone-8 (MK-8), menaquinone-9 (MK-9), menaquinone-10 (MK-10), menaquinone-11 (MK-11), and phylloquinone.
  • Phylloquinone can be obtained from plant sources such as green leafy vegetables and has a short half-life in the plasma, but it can be converted to menaquinone-4 (MK-4) by the endothelium, testes and pancreas. It can be synthesized by intestinal bacteria and is also found in cheeses.
  • vitamin K2 is provided through menaquinone-7 (MK-7).
  • the composition comprises about 10 ⁇ g to about 500 ⁇ g, preferably about 20 ⁇ g to about 400 ⁇ g, more preferably about 40 ⁇ g to about 300 ⁇ g, and most preferably about 50 ⁇ g to about 250 ⁇ g of menaquinone (MK-7). In some preferred embodiments wherein the composition is suitable for human use, the composition comprises about 75 ⁇ g to about 250 ⁇ g of menaquinone-7 (MK-7).
  • the method comprises administration of about 10 ⁇ g to about 500 ⁇ g, preferably about 20 ⁇ g to about 400 ⁇ g, more preferably about 40 ⁇ g to about 300 ⁇ g, and most preferably about 50 ⁇ g to about 250 ⁇ g of menaquinone-7 (MK-7).
  • the method comprises administration of about 75 ⁇ g to about 250 ⁇ g of menaquinone-7 (MK-7) to a subject.
  • the method comprises administration of about 0.1 ⁇ g/kg to about 8 ⁇ g/kg, preferably about 0.3 ⁇ g/kg to about 5 ⁇ g/kg, more preferably about 0.5 ⁇ g/kg to about 4.5 ⁇ g/kg, and most preferably about 0.75 ⁇ g/kg to about 3.5 ⁇ g/kg of menaquinone-7 (MK-7) to a subject.
  • the method comprises administration of about 1 ⁇ g/kg to about 3 ⁇ g/kg of menaquinone-7 (MK-7) to a subject.
  • the above amounts may refer to each dosage administration or a total daily dosage.
  • each of the components of the compositions and methods of the present invention for example, the sulforaphane precursor, the enzyme capable of converting the sulforaphane precursor to sulforaphane, the enzyme potentiator, and/or magnesium or a salt or complex thereof may be obtained from a natural source or produced synthetically.
  • the methods of the present invention may further comprise administration of one or more additional components.
  • the compositions of the present invention may further comprise one or more additional components.
  • the additional components may include active pharmaceutical ingredients, nutritional supplements, and nutritional extracts. Examples of additional components include, but are not limited, glucan, ursolic acid, quercetin or a derivative thereof, an aminosugar such as glucosamine, a glycosaminoglycan such as chondroitin, avocado/soybean unsaponifiables, vitamins such as vitamin K2, coffee fruit, magnesium, ursolic acid, proanthocyanidins, alpha- and beta-glucans, curcumin, phytosterols, phytostanols, and S-adenosylmethionine (SAMe).
  • SAMe S-adenosylmethionine
  • milk thistle Silybum marianum ) extract (silymarin), cranberry ( Vaccinium macrocarpon ) extract (proanthocyanidins, quercetin, and ursolic acid), turmeric ( Curcuma longa ), medicinal mushrooms (such as maitake shiitake, or reishi mushrooms).
  • the ratio of magnesium or a salt or complex thereof to sulforaphane or a derivative thereof is about 1:1 to about 50:1, preferably about 1.5:1 to about 20:1, more preferably about 1.75:1 to about 15:1, more preferably about 2:1 to about 11:1, and most preferably about 2:1 to about 8:1.
  • the ratio of magnesium or a salt or complex thereof to sulforaphane precursor is about 1:1 to about 25:1, preferably about 2:1 to about 10:1, more preferably about 3:1 to about 8:1, more preferably about 4:1 to about 7:1, and most preferably about 4:1 to about 6:1.
  • the composition comprises a unit dosage form, including but not limited to pharmaceutical dosage forms suitable for oral, rectal, intravenous, subcutaneous, intramuscular, transdermal, transmucosal, and topical.
  • the composition comprises an orally administrable dosage form or a rectally administrable dosage form.
  • orally administrable dosage forms include, but are not limited to a tablet, capsule, powder that can be dispersed in a beverage, a liquid such as a solution, suspension, or emulsion, a soft gel/chew capsule, a chewable bar, or other convenient dosage form known in the art.
  • the composition comprises a tablet, capsule, or soft chewable treat.
  • the orally administrable dosage forms may be formulated for immediate release, extended release or delayed release.
  • At least the sulforaphane precursor, the enzyme, and the enzyme potentiator are provided in a dosage form which allows for the release in an area of the gastrointestinal tract having a pH of at least 4 and preferably at least 5, such as the small intestine, preferably the duodenum.
  • at least the sulforaphane or derivative thereof and/or the broccoli extract or powder are provided in a dosage form which allows for the release in an area of the gastrointestinal tract having a pH of at least 4 and preferably at least 5, such as the small intestine, preferably the duodenum.
  • the magnesium or a salt or complex thereof and/or any optional additional components are also released in an area of the gastrointestinal tract having a pH of at least 4 and preferably at least 5, such as the small intestine, preferably the duodenum.
  • the small intestine includes the duodenum, jejunum, and ileum.
  • each of these components are released simultaneously or concomitantly (i.e., within a short period of time of each other).
  • This provides benefits over glucoraphanin-containing compositions formulated to release the glucoraphanin in an area of the gastrointestinal tract having a pH below 4, such as the stomach.
  • the acidic environment may divert conversion of sulforaphane precursor to other, physiologically inactive end products, such as sulforaphane nitrile and epithionitrile.
  • the compositions may comprise orally administrable compositions which comprise gastroprotective formulations, including enteric coated dosage forms or any dosage form which is resistant to degradation in an area of the gastrointestinal tract having pH below 4, such as the stomach.
  • the orally administrable composition may comprise a tablet or capsule comprising an enteric coating.
  • the enteric coating may comprise materials including, but not limited to cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid copolymer, methacrylic acid:acrylic ester copolymer, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose trimellitate, shellac, cellulose acetate trimellitate, carboxymethylethylcellulose, and mixtures thereof.
  • the enteric coating may comprise any suitable enteric polymers known in the art. In some embodiments, one or more of the components in the composition may be embedded in a matrix of enteric polymers.
  • the orally administrable compositions comprise a capsule that dissolves slowly in gastric acid and travels to the small intestine, such as DRCAPSTM acid resistant capsules, which are marketed by CAPSUGEL® or any other acid resistant capsules.
  • the orally administrable composition is surrounded by a coating that does not dissolve unless the surrounding medium is at a pH of at least 4, and more preferably at least 5.
  • a coating may be employed which controls the release by time, as opposed to pH, with the rate adjusted so that the components are not released until after the pH of the gastrointestinal tract has risen to at least 4, and more preferably at least 5.
  • a time-release formulation may be used to prevent gastric presence of the sulforaphane precursor, the enzyme capable of converting the sulforaphane precursor to sulforaphane, and the enzyme potentiator, or of the sulforaphane.
  • the coating layer(s) may be applied onto orally administrable composition using standard coating techniques.
  • the enteric coating materials may be dissolved or dispersed in organic or aqueous solvents.
  • the pH at which the enteric coat will dissolve can be controlled by a polymer, or combination of polymers, selected and/or ratio of pendant groups. For example, dissolution characteristics of the polymer film can be altered by the ratio of free carboxyl groups to ester groups.
  • Enteric coating layers also contain pharmaceutically acceptable plasticizers such as triethyl citrate, dibutyl phthalate, triacetin, polyethylene glycols, polysorbates or other plasticizers. Additives such as dispersants, colorants, anti-adhering and anti-foaming agents may also be included.
  • compositions may contain one or more non-active pharmaceutical ingredients (also known generally as “excipients”).
  • Non-active ingredients serve to solubilize, suspend, thicken, dilute, emulsify, stabilize, preserve, protect, color, flavor, and fashion the active ingredients into an applicable and efficacious preparation that is safe, convenient, and otherwise acceptable for use.
  • the excipients are preferably pharmaceutically acceptable excipients.
  • classes of pharmaceutically acceptable excipients include lubricants, buffering agents, stabilizers, blowing agents, pigments, coloring agents, flavoring agents, fillers, bulking agents, fragrances, release modifiers, adjuvants, plasticizers, flow accelerators, mold release agents, polyols, granulating agents, diluents, binders, buffers, absorbents, glidants, adhesives, anti-adherents, acidulants, softeners, resins, demulcents, solvents, surfactants, emulsifiers, elastomers and mixtures thereof.
  • the combination of (i) a sulforaphane precursor, preferably glucoraphanin, (ii) an enzyme capable of converting the sulforaphane precursor to sulforaphane, preferably a glucosidase enzyme, more preferably a thioglucosidase enzyme, and most preferably myrosinase, (iii) an enzyme potentiator, preferably an enzyme co-factor, more preferably ascorbic acid, and (iv) magnesium or a salt or complex thereof demonstrates a synergistic effect.
  • the combination of sulforaphane (or a derivative thereof) and magnesium or a salt or complex thereof demonstrates a synergistic effect.
  • Synergy refers to the effect wherein a combination of two or more components provides a result which is greater than the sum of the effects produced by the agents when used alone.
  • the synergistic effect is greater than an additive effect.
  • the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof has a statistically significant, greater effect compared to: (i) each component alone, (ii) the combination of sulforaphane precursor and the enzyme alone; and/or (iii) the combination of sulforaphane precursor, the enzyme, and the enzyme potentiator alone.
  • the combination of the sulforaphane precursor, the enzyme, the enzyme potentiator, and magnesium or a salt or complex thereof demonstrates synergy by having a statistically significant and/or greater than additive effect compared to the sulforaphane precursor alone and magnesium or a salt or complex thereof alone.
  • the combination of glucoraphanin, myrosinase, ascorbic acid, and magnesium or a salt or complex thereof has a synergistic effect compared to the combination of glucoraphanin, myrosinase, ascorbic acid alone; and compared to magnesium.
  • the combination of a sulforaphane (or a derivative thereof) and magnesium or a salt or complex thereof has a statistically significant and/or greater than additive effect than: (i) sulforaphane (or a derivative thereof) alone, and/or (ii) magnesium or a salt or complex thereof alone.
  • the combination of sulforaphane and glucan has a synergistic effect compared to sulforaphane alone, and magnesium alone.
  • the combination of broccoli extract or powder and magnesium or a salt or complex thereof has a statistically significant and/or greater than additive effect than: (i) broccoli extract or powder alone, and/or (ii) magnesium or a salt or complex thereof alone.
  • the combination of broccoli extract or powder and MK-7 has a synergistic effect compared to broccoli extract or powder alone, and magnesium alone.
  • the present invention provides methods of use, including methods of administration to a subject in need thereof.
  • the method comprises administration of the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and magnesium or a salt or complex thereof.
  • the method comprises administration of the combination of a sulforaphane or a derivative thereof and magnesium or a salt or complex thereof.
  • the method comprises administration of the combination of a broccoli extract or powder and magnesium or a salt or complex thereof.
  • the methods relate to treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of diseases or conditions such as those associated with the endothelium and cardiovascular system in a subject.
  • the diseases and conditions comprise atherosclerosis, ischemic heart disease, acute coronary syndrome, or arterial injury.
  • the methods may also relate to decreasing endothelial C-Reactive Protein to reduce vascular inflammation, increasing endothelial nitric oxide to improve vasodilitation for improved blood flow, decreasing atherosclerotic plaque calcification, reducing vascular damage or stiffness, and/or increasing bone mineral density.
  • the combination may be administered for decreasing levels or decreasing gene expression of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject.
  • the combination may be administered for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) in a subject.
  • diseases and conditions include, but are not limited to: atherosclerosis, inflammatory bowel disease, inflammatory lung disease, chronic liver disease such as cirrhosis, inflammatory rheumatic disease, osteoarthritis, gingivitis, asthma, psoriasis, Alzheimer's disease, ischemic heart disease, acute coronary syndrome, arterial injury, arteriogenesis, depression, type II diabetes, metabolic syndrome, colorectal cancer, migraines, asthma, renal disease, osteoporosis, lyme disease, ischemic disorders, neuropathy, gastrointestinal disease, and conditions occurring specifically in animals such as laminitis (e.g., in equines) and after heart worm treatments (e.g., in dogs and cats).
  • the compositions may also be administered after surgery.
  • the methods relate to providing a beneficial effect on biomarkers, and treating, preventing, reducing the occurrence of, decreasing the symptoms associated with abnormal levels of these biomarkers.
  • biomarkers include, but are not limited to NADPH-dependent enzymes, thioredoxin (TXN), thioredoxin reductase-1 (Txnrd-1), glutamate-cysteine ligase subunit (GCLC), sulfotransferase 1A1 (SULT1A1), heme oxygenase-1 (HMOX1), glutathione peroxidase-3 (GPx-3), glutathione S-transferse theta 2 (GSTT2), microsomal glutathione S-transferase 1 (MGST1), aldehyde oxidase (AOX1), aldo-keto reductase 1 B8 (Akr1 b8), flavin-containing monooxygenase 2 (FMO
  • TXN
  • Biomarkers include, but are not limited to cancer, pulmonary and central nervous system tuberculosis, multiple sclerosis, Crohn's disease, atherosclerosis, osteoarthritis, asthma, stroke, emphysema, diabetic nephropathy, chronic histiocytic intervillositis of the placenta, hypertension, abdominal aortic aneurysm, inflammatory bowel disease, chronic rhinosinusitis, coronary artery disease, and kidney disease.
  • the method comprises administering to a subject in need thereof a combination of sulforaphane and magnesium or a salt or complex thereof. In some embodiments the method comprises administering to a subject in need thereof a combination of broccoli extract or powder and magnesium or a salt or complex thereof. In some preferred embodiments, the method comprises administering to the subject a combination of glucoraphanin, myrosinase, ascorbic acid, and magnesium or a salt or complex thereof. In preferred embodiments, the combinations demonstrate a synergistic effect in the methods of the present invention.
  • one or more components of the combinations are administered together in one composition or dosage form, or separately, preferably within a period in which their therapeutic properties overlap.
  • the components of the combinations may be administered in two or more orally administrable compositions or dosage forms.
  • the sulforaphane precursor, the enzyme capable of converting the sulforaphane precursor to sulforaphane, and the enzyme potentiator are administered in one orally administrable dosage form, while the magnesium or a salt or complex thereof are administered in one or more separate or additional orally administrable dosage form(s).
  • the components of the combination are administered in one dosage form.
  • the combination may be administered at a frequency of 1 to 10 times daily, preferably 1 to 5 times daily, more preferably 1 to 3 times daily, and most preferably 1 time daily.
  • the dosages disclosed in this application refer generally to dosages suitable for humans. Dosage calculations can be determined by those of skilled in the art by evaluating body weight, surface area, metabolic rate, and species differences.
  • subject refers to any animal, including mammals and birds. Mammals include, but are not limited to, humans, dogs, cats, horses, cows, camels, elephants, lions, tigers, bears, seals, and rabbits. In preferred embodiments, the subjects comprise mammals that are not consumed as food, such as humans, cats, and dogs.
  • Glucoraphanin-containing broccoli seed extract (about 12% w/w), 50 mg to 5 grams Myrosinase-containing freeze-dried broccoli sprout powder, 25 mg to 500 mg Ascorbic acid, 5 mg to 500 mg Magnesium malate, providing 20 to 200 mg elemental magnesium.
  • HILIC Hydrophobic Interaction Chromatographic
  • Simulated Intestinal Fluid (SIF) powder a commercially supplied concentrate closely approximating the human intestinal content in terms of composition, pH and ionic strength, was used.
  • the experiment utilized a USP Dissolution Apparatus 2 (paddles), where into six dissolution vessels 500 mL of Simulated Intestinal Fluid was dispensed, along with 150 mg of freeze-dried broccoli sprout powder as a source of myrosinase.
  • MCP-1 monocyte chemoattractant protein
  • RAW cells were activated with 1 ⁇ g/mL lipopolysaccharide (LPS) for 30 minutes to stimulate the induction of MCP-1 gene expression.
  • LPS lipopolysaccharide
  • the cells were treated with one of the following: (i) DMSO (vehicle control), (ii) 0.5 ⁇ M SFN, (iii) 2.5 mM MgSO 4 , or (iv) the combination of 0.5 ⁇ M SFN and 2.5 mM MgSO 4 .
  • the MCP-1 levels were assessed via quantitative RT-PCR.
  • a subject presents with atherosclerosis and is suffering from symptoms including damage to the arteries and chest pain. She is administered a tablet containing glucoraphanin, myrosinase, ascorbic acid, and magnesium malate.
  • the tablet is an enteric coated formulation which releases the contents in the small intestine. After one month of daily administration of the tablet, the subject experiences modulation of surrogate biomarkers including interleukin-8 (IL-8) and/or monocyte chemoattractant protein-1 (MCP-1) which correlate with improvement in symptoms.
  • IL-8 interleukin-8
  • MCP-1 monocyte chemoattractant protein-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
US14/412,189 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium Abandoned US20150174093A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/412,189 US20150174093A1 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261668374P 2012-07-05 2012-07-05
US201261668328P 2012-07-05 2012-07-05
US201261668342P 2012-07-05 2012-07-05
US201261668364P 2012-07-05 2012-07-05
US201261668396P 2012-07-05 2012-07-05
US201261668386P 2012-07-05 2012-07-05
US201361794417P 2013-03-15 2013-03-15
US14/412,189 US20150174093A1 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
PCT/US2013/049224 WO2014008341A2 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/049224 A-371-Of-International WO2014008341A2 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/007,067 Continuation US20210008176A1 (en) 2012-07-05 2020-08-31 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium

Publications (1)

Publication Number Publication Date
US20150174093A1 true US20150174093A1 (en) 2015-06-25

Family

ID=49882601

Family Applications (14)

Application Number Title Priority Date Filing Date
US14/412,189 Abandoned US20150174093A1 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
US14/412,191 Active 2035-02-15 US10960057B2 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US14/412,176 Active US10688158B2 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
US14/412,180 Abandoned US20150174213A1 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid
US14/586,765 Active US9421183B2 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US14/586,698 Abandoned US20150118305A1 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid
US14/586,711 Abandoned US20150118304A1 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
US14/586,704 Abandoned US20150118306A1 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
US15/244,374 Active US10583178B2 (en) 2012-07-05 2016-08-23 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US16/701,644 Active US11654186B2 (en) 2012-07-05 2019-12-03 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US16/865,529 Active US11224639B2 (en) 2012-07-05 2020-05-04 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
US17/007,067 Pending US20210008176A1 (en) 2012-07-05 2020-08-31 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
US17/178,664 Active 2034-03-06 US12064471B2 (en) 2012-07-05 2021-02-18 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US17/560,494 Pending US20220118062A1 (en) 2012-07-05 2021-12-23 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder

Family Applications After (13)

Application Number Title Priority Date Filing Date
US14/412,191 Active 2035-02-15 US10960057B2 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US14/412,176 Active US10688158B2 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
US14/412,180 Abandoned US20150174213A1 (en) 2012-07-05 2013-07-03 Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid
US14/586,765 Active US9421183B2 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US14/586,698 Abandoned US20150118305A1 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid
US14/586,711 Abandoned US20150118304A1 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
US14/586,704 Abandoned US20150118306A1 (en) 2012-07-05 2014-12-30 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
US15/244,374 Active US10583178B2 (en) 2012-07-05 2016-08-23 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US16/701,644 Active US11654186B2 (en) 2012-07-05 2019-12-03 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US16/865,529 Active US11224639B2 (en) 2012-07-05 2020-05-04 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
US17/007,067 Pending US20210008176A1 (en) 2012-07-05 2020-08-31 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
US17/178,664 Active 2034-03-06 US12064471B2 (en) 2012-07-05 2021-02-18 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US17/560,494 Pending US20220118062A1 (en) 2012-07-05 2021-12-23 Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder

Country Status (11)

Country Link
US (14) US20150174093A1 (zh)
EP (5) EP3821895A1 (zh)
JP (10) JP6548573B2 (zh)
CN (2) CN108355136B (zh)
AU (9) AU2013286721B2 (zh)
CA (5) CA2877329C (zh)
ES (3) ES2877326T3 (zh)
PL (2) PL3409280T3 (zh)
RU (2) RU2666953C2 (zh)
TW (6) TW201402128A (zh)
WO (4) WO2014008366A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869853B2 (en) * 2011-10-31 2020-12-22 The Johns Hopkins University Compositions and methods for treating autism spectrum disorders
PL3409280T3 (pl) 2012-07-05 2021-10-18 Nutramax Laboratories, Inc. Kompozycje zawierające sulforafan i wyciąg lub proszek z ostropestu plamistego
CN105377252A (zh) 2013-03-14 2016-03-02 佛罗里达大学研究基金会 利用天然化合物和/或饮食调控癌症
US20140275235A1 (en) * 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
EP2968990A4 (en) * 2013-03-15 2016-08-24 Nutramax Lab Inc COMPOSITIONS COMPRISING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND PHYTOSTEROL OR PHYTOSTANOL
KR101515573B1 (ko) * 2014-11-07 2015-04-28 주식회사 파미니티 뉴그린 추출물을 유효성분으로 함유하는 해독용 조성물
BR112017012648B1 (pt) 2014-12-22 2020-12-08 Unilever N.V composição oral ou tópica e uso de um agonista de fator nuclear eritróide 2 relacionado ao fator 2 e um agonista do receptor hepático x como agentes ativos em uma composição oral ou tópica para beneficiar o crescimento da fibra capilar e/ou induzir o elemento de resposta antioxidante (are)
JP2018513123A (ja) 2015-03-12 2018-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
ES2818179T3 (es) 2015-06-26 2021-04-09 Plant Bioscience Ltd Glucorafanina para uso en el tratamiento y/o prevención de la diabetes mellitus
KR20180014194A (ko) * 2015-06-26 2018-02-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 천연 화합물 및/또는 식단을 사용하는 염증의 치료 방법
WO2017013239A1 (en) * 2015-07-22 2017-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Nrf2 activators for the treatment of mycobacterial infections
EP3123874B1 (en) * 2015-07-28 2018-05-02 Fundacíon Tecnalia Research & Innovation Formulations comprising glucosinolates and myrosinase
GB201605013D0 (en) * 2016-03-24 2016-05-11 Inst Of Food Res S-methylcysteine sulfoxide for prostate cancer treatment
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
US10925304B2 (en) * 2016-12-28 2021-02-23 Productive Aging Laboratory, Co., Ltd. Method for treating chronic fatigue syndrome, idiopathic chronic fatigue, and fibromyalgia
JP7057070B2 (ja) 2017-06-21 2022-04-19 カゴメ株式会社 粉末食品、及びその製造方法、並びに粉末食品のミロシナーゼ活性促進方法
CA3077235A1 (en) * 2017-09-28 2019-04-04 Commonwealth Scientific And Industrial Research Organisation Isothiocyanate containing brassicaceae products and method of preparation thereof
EP3762005A4 (en) * 2018-03-05 2022-03-30 Laila Nutraceuticals SYNERGIC HERBAL COMPOSITIONS FOR THE TREATMENT OF OBESITY AND OVERWEIGHT
CN116474079A (zh) * 2019-05-08 2023-07-25 深圳福山生物科技有限公司 包含萝卜硫苷的组合物及其用途
WO2022047212A1 (en) * 2020-08-27 2022-03-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating neurodegenerative disorders
US11801273B2 (en) 2020-12-23 2023-10-31 Church & Dwight Co., Inc. Compositions and methods to increase production of isothiocyanates
CN112574161A (zh) * 2021-01-19 2021-03-30 江苏德和生物科技有限公司 一种富含egc的非酯型茶多酚的制备方法
JP7288474B2 (ja) 2021-03-10 2023-06-07 プライムプラネットエナジー＆ソリューションズ株式会社 非水電解質二次電池の製造方法、および負極活物質
WO2022251524A1 (en) 2021-05-26 2022-12-01 Nutramax Laboratories, Inc. Compositions comprising sulforaphane or a sulforaphane precursor and moringa plant components
US20230364133A1 (en) * 2022-05-10 2023-11-16 Melaleuca, Inc. Dietary supplement compositions
WO2024064264A2 (en) * 2022-09-21 2024-03-28 Lile Method Research, Llc Compositions and methods for increasing glutathione levels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511675B2 (en) * 2000-06-12 2003-01-28 Access Business Group International, Llc Composition and method for correcting a dietary phytochemical deficiency
US20090247477A1 (en) * 2005-04-29 2009-10-01 John Hopkins School Of Medicine Methods of suppressing uv light-induced skin carcinogenesis

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3442639A1 (de) 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
JPH07252148A (ja) * 1994-10-08 1995-10-03 Masahiro Nagahama 糖尿病治療薬
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
US5725895B1 (en) 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US5686108A (en) * 1995-09-27 1997-11-11 Amway Corporation Brassica vegetable supplement and process for manufacture
JP3041232B2 (ja) 1995-11-16 2000-05-15 日本ケミカルリサーチ株式会社 癌転移抑制剤
JP2918834B2 (ja) 1995-12-25 1999-07-12 美穂 田中 シイタケエキス粉末の製造法
JP2859843B2 (ja) 1996-03-08 1999-02-24 株式会社雪国まいたけ マイタケから抽出した抗腫瘍物質
US6242018B1 (en) 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
WO1999043336A1 (en) 1998-02-27 1999-09-02 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US20010000472A1 (en) 1998-02-27 2001-04-26 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US6521818B1 (en) 1998-07-01 2003-02-18 John Hopkins School Of Medicine Development of novel highly chemoprotectant crucifer germplasm
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
JP4308350B2 (ja) 1998-11-27 2009-08-05 小林製薬株式会社 シイタケ菌糸体抽出物を含有するｌａｋ活性スクリーニング物質およびそれを用いたｌａｋ活性スクリーニング法
US20030091518A1 (en) 1999-12-20 2003-05-15 Gilles Pauly Cosmetic and/or pharmaceutical preparations
WO2001054673A1 (en) 2000-01-31 2001-08-02 The University Of British Columbia Method for preparing and administering medicinal plant material
CN100522154C (zh) * 2000-08-21 2009-08-05 杰德W·费伊 异硫氰酸酯类化合物在制备治疗螺杆菌感染的药物中的用途
JP3504612B2 (ja) 2000-12-28 2004-03-08 株式会社東洋新薬 栄養補助食品
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
US8017160B2 (en) * 2003-08-15 2011-09-13 Russell Jaffe Enhancement of magnesium uptake in mammals
JP2005073508A (ja) 2003-08-28 2005-03-24 Asahi Denka Kogyo Kk 食用または薬用植物を含有する飲料
ITMI20040696A1 (it) 2004-04-08 2004-07-08 Aboca S P A Composizioni per tisane arricchite con estratti secchi vegetali
JP4126053B2 (ja) * 2004-05-06 2008-07-30 堯 近藤 鹿角霊芝を含有した健康食品の製造方法
WO2005107496A1 (ja) 2004-05-06 2005-11-17 Maruasaen Corporation 生キノコエキス製造方法、エキス及びエキス配合物
RU2292899C2 (ru) 2004-06-29 2007-02-10 Дмитрий Николаевич Мясников Средство и способ профилактики и уменьшения неблагоприятных проявлений острой алкогольной интоксикации (варианты) и способ получения средства
US20060264497A1 (en) * 2005-03-28 2006-11-23 Zeligs Michael A Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
EP1709969A1 (en) 2005-04-07 2006-10-11 Praktijkonderzoek Plant en Omgeving B.V. Health promoting dairy and food products containing mushroom glucan produced through fermentation of Grifola frondosa
KR100661032B1 (ko) * 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
US8124135B2 (en) 2005-05-24 2012-02-28 Vdf Futureceuticals, Inc. Compositions and methods for reduction of LDL oxidation
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
DE102005033616A1 (de) * 2005-07-19 2007-01-25 Biopro Ag Biological Products Verfahren zur Herstellung von Extrakten aus Brassica-Arten und ihre Verwendung
US20070021376A1 (en) * 2005-07-21 2007-01-25 Suracell, Inc. Supplement composition and method of use in enhancement of methylation process
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
RU2319494C2 (ru) * 2005-11-11 2008-03-20 РАНХЕЛЬ Хосе Анхель ОЛАЛДЕ Синергетическая композиция растительного происхождения (варианты), способ лечения заболеваний с ее использованием
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
MY166532A (en) * 2006-02-10 2018-07-10 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
JP2007320947A (ja) * 2006-05-30 2007-12-13 Shonan Institute For Medical & Preventive Science 血糖値上昇抑制剤
JP4677033B2 (ja) 2006-06-02 2011-04-27 株式会社ハイマート マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物
WO2008002175A1 (fr) * 2006-06-29 2008-01-03 Vulf Abramovich Laskin Régime hebdomadaire destiné aux patients oncologiques et aux personnes ayant une durée de vie remarquablement longue
US7803605B2 (en) 2006-07-14 2010-09-28 National Institute Of Advanced Industrial Science And Technology Breeding method for yeast, yeast and a production method for glycoprotein or beta-glucan
KR20080030722A (ko) 2006-10-02 2008-04-07 신현길 브로콜리가루가 첨가된 빵의 제조방법
WO2008115583A1 (en) * 2007-03-21 2008-09-25 John Mini Herbal treatments
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
US20080311192A1 (en) * 2007-06-12 2008-12-18 Kraft Foods Holdings, Inc. Enteric-Coated Glucosinolates And Beta-Thioglucosidases
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
CZ305673B6 (cs) 2007-08-02 2016-02-03 Irel, Spol. S R. O. Mechanicky upravený plod ostropestřce mariánského a způsob jeho úpravy
ES2325291B1 (es) 2007-10-04 2010-04-22 Madaus S A "uso de un extracto de silybum marianum"
EP2205237A1 (en) 2007-10-16 2010-07-14 Johns Hopkins University Methods for protecting the skin from radiation insults
WO2009063885A1 (ja) 2007-11-13 2009-05-22 Heimat Co., Ltd. マイタケ抽出物及びこれを含むヒアルロン酸（ヒアルロナン）産生を促進するための組成物
ITMI20080172A1 (it) * 2008-02-05 2009-08-06 Bios Line Spa Formulazioni orali per la protezione delle vie respiratorie con particolare riferimento ai fenomeni infiammatori e neoplastici
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US7923044B2 (en) * 2008-07-15 2011-04-12 Paradise Herbs & Essentials, Inc. Composition for high-ORAC value dietary supplement
KR20100016876A (ko) * 2008-08-05 2010-02-16 오춘근 다이어트 및 당뇨에 유용한 기능성 혼합곡물
EP2213280A1 (en) 2009-01-30 2010-08-04 DSM IP Assets B.V. Formulations comprising glucosinolate and myrosinase
CN101514174B (zh) * 2009-02-24 2011-11-02 黑龙江八一农垦大学 一种从西兰花芽苗菜中提取多功能莱菔硫烷的方法
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
JP2010259424A (ja) * 2009-05-11 2010-11-18 Hisako Arai 簡単に摂取できる副食の調理法。
WO2011003045A1 (en) * 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
WO2011060585A1 (zh) * 2009-11-20 2011-05-26 天津天狮生物发展有限公司 含有五色果蔬精华的咀嚼片剂及其制备方法
WO2011076154A1 (en) 2009-12-22 2011-06-30 Irel, Spol. S R.O. Feed supplement based on milk thistle, method of its production and its use
KR101079643B1 (ko) 2010-01-12 2011-11-04 이현재 신장 기능 강화용 식품 조성물 및 그 제조방법
WO2011099665A1 (ko) 2010-02-12 2011-08-18 주식회사 케이씨아이 천연 원료 추출물을 포함하는 항균 조성물, 복합 천연 방부제 및 이들의 제조방법
US20110206721A1 (en) * 2010-02-19 2011-08-25 Vijaya Nair Fermented soy nutritional supplements including mushroom components
US20120021079A1 (en) 2010-02-23 2012-01-26 Brett Justin West Garcinia Mangostana L. and Iridoid Based Formulations
US20110262595A1 (en) 2010-04-21 2011-10-27 Naturalife Asia Co., Ltd. Antioxidant nutritional supplement
US20110287109A1 (en) * 2010-05-24 2011-11-24 Max International, Llc Compositions And Beverages Comprising Nutrients, Vitamins, Sugars, Cysteine, And/Or Sugar-Cysteine Products
DE102010022587A1 (de) * 2010-05-28 2011-12-01 Wilfried Rühle Magensaftresistente Zusammensetzung zur oralen Einnahme von pflanzenbasierten Komponenten zur Prävention von Darmkrebs
CN102450534A (zh) * 2010-10-26 2012-05-16 宁波海逸生物科技有限公司 一种增强免疫力功能的西灵胶囊配方
ES2382299B1 (es) 2010-11-11 2013-05-07 Consejo Superior De Investigaciones Científicas (Csic) Polvo vegetal para alimentación y protección vegetal y métodos de preparación.
NZ589578A (en) * 2010-11-29 2013-03-28 Comvita Ltd Cancer Chemoprotective Product including glucosinolate and myrosinase
CN102526455A (zh) 2010-12-16 2012-07-04 天津中敖生物科技有限公司 具有清肺化痰功能的家畜用中药组合物及其制备方法
CN103458921B (zh) * 2011-02-22 2016-05-11 考迪尔种子公司 喷雾干燥的黑芥子酶和用于生产异硫氰酸酯的用途
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
US20130045273A1 (en) * 2011-08-19 2013-02-21 John Cuomo Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds
CN102526445B (zh) * 2011-11-07 2013-12-11 宁波海逸生物科技有限公司 一种增强免疫力、缓解体力疲劳、抗肿瘤功能的保健药物配方
PL3409280T3 (pl) * 2012-07-05 2021-10-18 Nutramax Laboratories, Inc. Kompozycje zawierające sulforafan i wyciąg lub proszek z ostropestu plamistego

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511675B2 (en) * 2000-06-12 2003-01-28 Access Business Group International, Llc Composition and method for correcting a dietary phytochemical deficiency
US20090247477A1 (en) * 2005-04-29 2009-10-01 John Hopkins School Of Medicine Methods of suppressing uv light-induced skin carcinogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Liang et al ("Effects of metal ions on myrosinase activity and the formation of sulforaphane in broccoli seed," Journal of Molecular Catalysis B: Enzymatic 43 (2006) 19–22 *

Also Published As

Publication number Publication date
EP2849737A2 (en) 2015-03-25
JP7232806B2 (ja) 2023-03-03
WO2014008361A3 (en) 2014-02-20
EP3409280A1 (en) 2018-12-05
WO2014008361A2 (en) 2014-01-09
JP7109132B2 (ja) 2022-07-29
CA2877356A1 (en) 2014-01-09
CN108355136A (zh) 2018-08-03
AU2013286721B2 (en) 2018-04-26
US10688158B2 (en) 2020-06-23
TW201402128A (zh) 2014-01-16
US20210008176A1 (en) 2021-01-14
CA3112680A1 (en) 2014-01-09
ES2700223T3 (es) 2019-02-14
CN104427981B (zh) 2018-05-25
US20150110872A1 (en) 2015-04-23
WO2014008341A2 (en) 2014-01-09
WO2014008366A3 (en) 2014-03-13
AU2022203801A1 (en) 2022-06-23
US11654186B2 (en) 2023-05-23
US20200261553A1 (en) 2020-08-20
CN104427981A (zh) 2015-03-18
WO2014008353A2 (en) 2014-01-09
RU2015103498A (ru) 2016-08-27
WO2014008341A3 (en) 2014-02-27
US11224639B2 (en) 2022-01-18
US20200101143A1 (en) 2020-04-02
US12064471B2 (en) 2024-08-20
EP3821895A1 (en) 2021-05-19
US20150118304A1 (en) 2015-04-30
RU2666953C2 (ru) 2018-09-13
RU2018130094A3 (zh) 2022-04-19
TWI637745B (zh) 2018-10-11
AU2013286713A1 (en) 2015-01-22
CA2877338C (en) 2022-10-11
CA2877338A1 (en) 2014-01-09
ES2755757T3 (es) 2020-04-23
US20210169997A1 (en) 2021-06-10
TW201402131A (zh) 2014-01-16
RU2018130094A (ru) 2018-10-04
US20150174213A1 (en) 2015-06-25
AU2013286721A1 (en) 2015-01-22
JP6548573B2 (ja) 2019-07-24
JP2022059053A (ja) 2022-04-12
CN108355136B (zh) 2021-12-07
PL3409280T3 (pl) 2021-10-18
TWI606830B (zh) 2017-12-01
US9421183B2 (en) 2016-08-23
JP2024023619A (ja) 2024-02-21
CA2877356C (en) 2021-05-11
US20150118305A1 (en) 2015-04-30
AU2020223773A1 (en) 2020-09-17
JP2021001229A (ja) 2021-01-07
AU2020217440A1 (en) 2020-09-03
AU2018204604B2 (en) 2020-06-04
EP2849737B1 (en) 2019-09-11
EP3666277A1 (en) 2020-06-17
CA3112680C (en) 2023-07-25
JP2015522039A (ja) 2015-08-03
CA2877393A1 (en) 2014-01-09
AU2018204604C1 (en) 2020-11-19
AU2018204283B2 (en) 2020-07-09
RU2680387C2 (ru) 2019-02-20
JP7068383B2 (ja) 2022-05-16
TW201402130A (zh) 2014-01-16
JP2022137226A (ja) 2022-09-21
RU2015103499A (ru) 2016-08-27
JP6777366B2 (ja) 2020-10-28
CA2877329A1 (en) 2014-01-09
ES2877326T3 (es) 2021-11-16
JP2021038258A (ja) 2021-03-11
AU2020217440B2 (en) 2022-09-08
TWI580425B (zh) 2017-05-01
JP6436443B2 (ja) 2018-12-12
US20150147352A1 (en) 2015-05-28
AU2018204604A1 (en) 2018-07-12
EP2849736A2 (en) 2015-03-25
US10583178B2 (en) 2020-03-10
TW201717964A (zh) 2017-06-01
EP2849736B1 (en) 2018-09-05
US10960057B2 (en) 2021-03-30
JP2020128416A (ja) 2020-08-27
CA2877329C (en) 2020-01-07
CA2877393C (en) 2020-01-07
US20150196525A1 (en) 2015-07-16
TW201618791A (zh) 2016-06-01
US20160354448A1 (en) 2016-12-08
PL2849736T3 (pl) 2019-06-28
EP3409280B1 (en) 2021-04-14
EP2849737A4 (en) 2016-07-13
US20180200344A9 (en) 2018-07-19
AU2020223773B2 (en) 2023-04-27
WO2014008366A2 (en) 2014-01-09
AU2013286713B2 (en) 2018-04-05
JP2015523366A (ja) 2015-08-13
AU2018204283A1 (en) 2018-07-05
EP2849736A4 (en) 2016-07-13
AU2024205248A1 (en) 2024-08-22
US20220118062A1 (en) 2022-04-21
JP2019014763A (ja) 2019-01-31
JP2019023245A (ja) 2019-02-14
JP7458443B2 (ja) 2024-03-29
TW201402129A (zh) 2014-01-16
US20150118306A1 (en) 2015-04-30
WO2014008353A3 (en) 2014-03-06
AU2023208131A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
US20210008176A1 (en) Compositions comprising sulforaphane or a sulforaphane precursor and magnesium
RU2785683C2 (ru) Композиции, содержащие сульфорафан или предшественник сульфорафана и экстракт или порошок молочного чертополоха

Legal Events

Date Code Title Description
AS Assignment

Owner name: NUTRAMAX LABORATORIES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CORNBLATT, BRIAN;CORNBLATT, GRACE;BZHELYANSKY, ANTON;AND OTHERS;SIGNING DATES FROM 20150205 TO 20150423;REEL/FRAME:035559/0565

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION